LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer  by Slater, Emily P. et al.
LCN2 and TIMP1 as Potential
Serum Markers for the
Early Detection of Familial
Pancreatic Cancer1
Emily P. Slater*, Volker Fendrich*,
Konstantin Strauch†,‡, Susanne Rospleszcz†,‡,
Annette Ramaswamy§, Elvira Matthäi*,
Brunhilde Chaloupka*, Thomas M. Gress¶,
Peter Langer* and Detlef K. Bartsch*
*Department of Surgery, Philipps University, Marburg,
Germany; †Institute of Medical Informatics, Biometry
and Epidemiology, Chair of Genetic Epidemiology,
Ludwig-Maximilians-Universität, Munich, Germany;
‡Institute of Genetic Epidemiology, Helmholtz Zentrum
München, German Research Center for Environmental
Health, Neuherberg, Germany; §Department of Pathology,
Philipps University, Marburg, Germany; ¶Department of
Gastroenterology, Philipps University, Marburg, Germany
Abstract
High-risk individuals of familial pancreatic cancer (FPC) families are considered to be good candidates for screening
programs to detect early PC or its high-grade precursor lesions, especially pancreatic intraepithelial neoplasia (PanIN)
2/3 lesions. There is a definite need for diagnostic markers as neither reliable imaging methods nor biomarkers are
available to detect these lesions. On the basis of a literature search, the potential serum markers neutrophil gelatinase-
associated lipocalin (LCN2), metallopeptidase inhibitor 1 (TIMP1), chemokine (C-X-C motif) ligand 16 (CXCL16), IGFBP4,
and iC3a, which were first tested in transgenic KrasLSL.G12D/+;p53R172H/+;Pdx1-Cre mice, were identified. ELISA analy-
ses of LCN2, TIMP1, and CXCL16 revealed significantly higher levels in mice with PanIN2/3 lesions or PC compared
to mice with normal pancreata or PanIN1 lesions. Analysis of preoperative human serum samples from patients with
sporadic PC (n = 61), hereditary PC (n = 24), chronic pancreatitis (n = 28), pancreatic neuroendocrine tumors
(n = 11), and FPC patients with histologically proven multifocal PanIN2/3 lesions (n = 3), as well as healthy control
subjects (n = 20), confirmed significantly higher serum levels of LCN2 and TIMP1 in patients with PC and multifocal
PanIN2/3 lesions. The combination of LCN2 and TIMP1 as a diagnostic test for the detection of PC had a sensitivity,
specificity, and positive predictive value of 100%each. Although this preliminary finding needs to be validated in a large
series of individuals at high risk for FPC, serummeasurement of LCN2 and TIMP1might be a promising screening tool.
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Introduction
Familial pancreatic cancer (FPC) is a rare but established inherited
tumor predisposition syndrome that accounts for about 3% of all
PC cases [1,2]. FPC defines families with at least two first-degree
relatives with confirmed PC that do not fulfill the criteria of other
inherited tumor syndromes with an increased risk of the development
of PC, such as Peutz-Jeghers syndrome or hereditary pancreatitis [3,4].
The major gene defect is yet to be identified, although germ line
mutations in the BRCA2, PALB2, and ATM are causative in about
15% of FPC families [5 6 7 8, reviewed in 4]. A 2003 consensus
conference considered it appropriate to perform PC screening for those
individuals who are considered at high risk of developing the disease
[3]. Individuals with at least a 10-fold increased risk of PC, such as
members of FPC families with two or more affected first-degree rela-
tives, are deemed good candidates for screening. Although reliable
imaging tools as well as biomarkers for the early detection of PC or,
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even better, its high-grade precursor lesions, pancreatic intraepithelial
neoplasia (PanIN) 2/3, are still lacking, magnetic resonance imaging
(MRI) and endoscopic ultrasonography are currently felt to be the best
imaging modalities for screening [4]. Thus, there is a definite need for
biomarkers that facilitate PC screening in this setting. We performed a
literature search that led to the selection of five markers: IGFBP4 [9],
chemokine (C-X-C motif) ligand 16 (CXCL16) [10], metallopeptidase
inhibitor 1 (TIMP1) [9], iC3b [11], and neutrophil gelatinase-associated
lipocalin (LCN2/NGAL) [12–14]. Sporadic and familial PC are char-
acterized by progression from PanIN with different grades of dysplasia
(PanIN 1 to 3) toward invasive cancer. Pancreatic specimens of FPC
patients often reveal a so-called “PanIN disease” [15]. The stepwise pro-
gression comprises activating mutations of the Kras oncogene and in-
activation of the ARF-p53 tumor suppressor pathway in the great
majority of cases [16]. Nowadays, genetically engineered mouse models
of PC that closely recapitulate the histopathogenesis of the human disease
and include the KrasLSL.G12D/+;p53R172H/+;Pdx1-Cre (KPC) mice that
develop a spectrum of premalignant PanIN lesions and ultimately inva-
sive carcinoma in 5 to 10 months [17–19] are available. Because pancre-
atic specimens of FPC patients often reveal a so-called “PanIN disease”
[15], this mouse model was valuable for the study presented.
Materials and Methods
Literature Search
Protein markers overexpressed at the protein and RNA levels in
human PC and mouse models of PC were compiled by searching
the PubMed and MEDLINE databases for articles published from
1 January 1990 to 31 March 2010. The search terms “pancreatic
cancer” or “familial pancreatic cancer” and “protein markers” or “bio-
marker”, or “early detection”, or “diagnostic test” were used. A second-
level manual search included the reference list of the articles considered
to be of interest. The literature search and study selection were per-
formed by two authors (D.K.B. and E.P.S.). More recent publica-
tions were prioritized. This literature search led to the selection of
five markers: IGFBP4 [9], CXCL16 [10], TIMP1 [9], iC3b [11],
and LCN2/NGAL [12–14].
Transgenic Mouse Lines
Conditional LsL-Trp53R172H, LsL-KrasG12D, and Pdx1-Cre [14]
strains were interbred to obtain LsL-KrasG12D;LsL-Trp53R172H;
Pdx1-Cre triple mutant animals on a mixed 129/SvJae/C57Bl/6 back-
ground as described before [16]. The generation of RIP1-Tag2 mice
as a model of pancreatic islet cell carcinogenesis has been previously
reported [20]. All experiments were approved by the local committee
for animal care and use. Animals were maintained in a climate-controlled
room kept at 22°C, exposed to a 12:12-hour light-dark cycle, fed stan-
dard laboratory chow, and given water ad libidum.
For genotyping, genomic DNA was extracted from tail cuttings
using the REDExtract-N-AmpTM Tissue Polymerase Chain Reaction
(PCR) Kit (Sigma-Aldrich, St Louis, MO). Three PCRs were carried
out for each animal to test for the presence of the oncogenic Kras (using
LoxP) primers, p53, and Pdx1-Cre transgene constructs (using Cre-
specific primers), respectively, or one PCR to test for the presence of
Tag2 in the endocrine mice.
Mice were killed, blood was collected from the thoracic cavity for
serum, and the pancreas was removed and inspected for grossly visible
tumors and preserved in 10% formalin solution (Sigma-Aldrich) for
histology. Formalin-fixed, paraffin-embedded tissues were sectioned
(4 μm) and stained with hematoxylin and eosin (H&E). Six sections
(100 μm apart) of pancreatic tissues were histologically evaluated by
an experienced pathologist (A.R.) blinded to the experimental groups.
mPanIN lesions were classified according to histopathologic criteria as
recommended elsewhere [21].
The pancreata of all KPCmice sacrificed were histologically analyzed
and graded according to the highest lesions found before conducting
the ELISAs [17,18]. The mice analyzed exhibited a range of PanINs
(1 to 3; n = 27), as well as invasive carcinoma (n = 9). Wild-type mice
of the same background and age served as controls (n = 20).
Human Samples
Serum samples from patients were obtained at the time of diagnosis
following informed consent according to the ethics protocol from our
university (No. 36/1997; 5/2003). Samples were stored at −80°C.
ELISAs of the three biomarkers LCN2, TIMP1, and CXCL16 were
performed in the preoperative sera of patients who underwent potential
curative pancreatic surgery for sporadic PC (n = 61), FPC (n = 24),
chronic pancreatitis (CP; n = 28), and pancreatic endocrine tumors
(n = 11), respectively. In addition, three FPC patients who underwent
prophylactic surgery and revealed multifocal PanIN2/3 lesions with-
out invasive PC upon histology were analyzed. Twenty healthy sub-
jects aged between 38 and 63 years served as controls. The study was
approved by the local ethics committee and all patients included in
the analysis gave their informed consent (No. 36/1997; last amend-
ment 5/2009).
Results
In a first step, the potential serummarkers IGFBP4, CXCL16, TIMP1,
iC3a, and LCN2 were tested in the serum of the KPC mice to deter-
mine their expression in mice with normal pancreas, different grades
of PanINs (1 to 3), and invasive cancer. The serum drawn from mice
Table 1. ELISA Results from Mouse Serum.
Marker Control PanIN1 P Value PanIN2/3 P Value
(vs Con)
P Value
(vs PanIN1)
Invasive CA P Value
(vs Con)
P Value
(vs PanIN1)
CXCL16 0.65 ng/ml (N = 9) 0.69 ng/ml (N = 5) .753* 1.45 ng/ml (N = 8) .0004 .0152 6.96 ng/ml (N = 6) .0001 .0001
TIMP1 2.9 ng/ml (N = 6) 4.6 ng/ml (N = 6) .035 6.6 ng/ml (N = 10) .0021 .0805* 35.8 ng/ml (N = 6) .0123 .0162
LCN2 165 ng/ml (N = 17) 337 ng/ml (N = 16) .0008 1937 ng/ml (N = 10) .0001 .0001 4249 ng/ml (N = 9) <.0001 .0001
ELISA tests were performed according to the recommendations by the manufacturer for CXCL16, TIMP1, and LCN2/NGAL (R&D Systems). The ELISA plate was measured on an Emax plate reader
(Molecular Devices, Munich Germany) and then analyzed with SOFTmax Pro (Version 3-0) software.
To determine whether our assays show differences between healthy (wild-type) and affected (transgenic) animals, we evaluated serum protein levels from each of the ELISAs using an unpaired t test.
Values of P < .05 were considered to be statistically significant.
*Not statistically significant.
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at the time of sacrifice was tested in commercial ELISA tests specific
for each of the five chosen markers. Following preliminary testing,
the markers IGFBP4 and iC3a were excluded from further analysis
as the values did not discriminate between affected and unaffected
animals. In contrast, mouse CXCL16, mouse TIMP1, and mouse
LCN2 ELISAs (R&D Systems, Wiesbaden, Germany) showed signifi-
cantly higher serum levels in mice with PanIN2/3 lesions or invasive
PC compared to controls. The results were also significant when com-
paring PC to PanIN1 levels. In addition, the serum levels of both
CXCL16 and LCN2were also higher in PanIN2/3 compared to PanIN1
mice. The results of the mouse ELISAs are shown in Table 1 and
Figure 1A. On the basis of these data, LCN2 was the most promising
serum biomarker for the early detection of PC in mice. These findings
for LCN2 raised the question as to the cellular source of the antigen. To
confirm that the serum LCN2 detected by the ELISA methodology was
derived from pancreatic lesions, we performed immunohistochemical
analysis with an anti-LCN2 antibody (R&D Systems) in pancreatic tis-
sue from affected and unaffected mice. The level of expression of LCN2
was higher in PanIN lesions and PC than in control tissue (Figure 2). All
mice with an increased level of serum LCN2 also showed strong positive
immunostaining of high-grade PanIN lesions and cancer cells (data not
shown). The promising results in KPC mice prompted us to perform
ELISAs of the three biomarkers LCN2, TIMP1, and CXCL16 in hu-
man samples. These results are shown in Figure 1B.
Receiver operating characteristic (ROC) curves were calculated to
determine the ability of each individual marker, as well as of logistic
Figure 1. Scatter plots. (A) ELISA data from mouse serum. The results of mouse CXCL16, mouse TIMP1, and mouse LCN2/NGAL ELISAs
were tested on mouse serum from control and transgenic mice with PanIN1, PanIN2/3, invasive pancreatic carcinoma (CA), or endocrine
tumors. The dark gray lines indicate median values and the interquartile range. The light gray lines indicate mean values. (B) ELISA data
from human serum. The results of human CXCL16, human TIMP1, and human LCN2/NGAL ELISAs were tested on human serum from
control and patients with CP, sporadic PC (PDAC), FPC, or pancreatic endocrine tumors (endocrine). The dark gray lines indicate median
values and the interquartile range. The light gray lines indicate mean values.
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models fitted with combinations of ELISA markers as predictors, to
distinguish between pairs of different entities or so-called diagnostic
groups. The results of the ROC curve analyses, including sensitivity,
specificity, and cutoff value to distinguish between the two groups with
the highest discrimination, are presented in Table 2. Due to the limited
number of patients with multifocal PanIN2/3 lesions from FPC fam-
ilies (n = 3), results from these patients could not be included in the
statistical analysis. They rather served as a first test whether the model
correctly classified them as high-risk individuals. As in the KPC mice,
LCN2 was the most sensitive and specific marker for the discrimination
between normal individuals and FPC (sensitivity, 100%; specificity,
100%) or sporadic PC (sensitivity, 92%; specificity, 100%). LCN2
had its lowest sensitivity, 73% and 82%, in discrimination between
normal individuals and individuals with endocrine tumors and CP,
respectively. However, this is not a major drawback for the clinical
setting for several reasons: 1) endocrine neoplasms rarely occur within
the setting of FPC and also present an indication for operation itself,
2) patients with FPC rarely present advanced changes of CP on histo-
pathologic examination [22], and 3) high-risk individuals of FPC
families do not have as severe CP as the patients with end-stage CP
that were used here for serum collection. Overall, the combination of
markers LCN2 and TIMP1 could discriminate PC, FPC, and CP from
controls, as well as FPC from CP with an area under the curve (AUC)
of 92% to 100%, whereas the AUC (82%) was slightly lower for the
discrimination between individuals with endocrine pancreatic tumors
and healthy individuals. This might be partially explained by the low
number (n = 11) of benign and malignant endocrine tumors that
were included in the study (Table 2). A better discrimination could
be achieved between FPC and endocrine tumors (AUC of 98.5%).
A sufficient number of FPC patients with histologically confirmed
multifocal PanIN2/3 lesions for a true validation of the proposed
marker combination were not available, because these patients are
Figure 2. Immunochemical staining of sections from wild-type (WT, A) and KPC mice with PanIN1B-2 (B) and PanIN2/3 (C) lesions and
carcinoma (D, E) using anti-LCN2 antibody (AF 1857 [23]; R&D Systems, 1:1000 dilution). Strong, positive (brown) staining is apparent in
the ductal lesions, whereas the normal/wild-type tissue is only weakly stained. For immunolabeling, formalin-fixed and paraffin-embedded
archived tumor samples and corresponding normal tissues were stained as previously described [19]. Briefly, slides were heated to 60°C for
1 hour, deparaffinized using xylene, and hydrated by a graded series of ethanol washes. Antigen retrieval was accomplished by microwave
heating in 10mMsodiumcitrate buffer of pH 6.0 for 10minutes. For immunohistochemistry, endogenous peroxidase activity was quenched
by 10-minute incubation in 3% H2O2. Nonspecific binding was blocked with 10% serum. Sections were then probed with lipocalin antibody
(R&D Systems; AF1857) affinity-purified polyclonal goat IgG (1:1000) overnight at 4°C. Bound antibodies were detected using the avidin-
biotin complex peroxidase method (ABC Elite Kit; Vector Labs, Burlingame, CA). Final staining was developed with the Sigma FAST DAB
Peroxidase Substrate Kit (Sigma, Deisenhofen, Germany).
Table 2. Results of ROC Curves of ELISA Analyses.
LCN2/NGAL TIMP1 CXCL16 TL* CTL†
con-FPC Sensitivity 1 0.80 0.81 1 1
Specificity 1 0.85 1 1 1
AUC 1 0.885 0.934 1 1
Cutoff 42.3–102 273 4.17
con-PC Sensitivity 0.92 0.75 0.62 0.93 0.93
Specificity 1 0.85 0.85 1 1
AUC 0.956 0.812 0.778 0.967 0.971
Cutoff 43.4 282 3.7
con-Endo Sensitivity 0.73 0.60 0.70 0.82 0.73
Specificity 1 0.69 0.54 0.82 1
AUC 0.811 0.600 0.612 0.818 0.802
Cutoff 69 231 2.9
con-CP Sensitivity .825 0.47 0.35 0.89 .89
Specificity 1 0.69 1 1 1
AUC 0.859 0.456 0.473 0.912 0.918
Cutoff 48.4 243 4
CP-FPC Sensitivity 0.90 0.80 0.95 0.92 0.92
Specificity 0.92 0.71 0.68 1 1
AUC 0.958 0.775 0.864 0.983 0.981
Cutoff 176 273 3.4
FPC-Endo Sensitivity 0.85 0.70 0.86 0.92 0.92
Specificity 1 0.80 0.80 1 1
AUC 0.968 0.810 0.871 0.985 0.985
Cutoff 301 318 3.69
For the human samples, ROC curves were used to determine the ability of each individual marker to
distinguish between the diagnostic groups. The discrimination was determined for each of the follow-
ing pairs with the group to the right defined as affected: control < endocrine < CP < duAdCa or FPC.
This allowed for the determination of sensitivity (true-positive rate) and specificity (true-negative rate)
as well as the determination of the AUC as a performance index. For the combinations of two or three
markers, a logistic regression for binary outcome, affected or not, was performed as a first step to
obtain a model with regression coefficients, which reflect the strength of influence for each marker
on the probability that one of the two outcomes is present in an individual. The resulting logistic
model was applied to determine the probability for each person to have one of the two outcomes.
These individual probabilities based on the marker combination were then used to create an ROC
curve, similar to the serum protein levels when looking only at a single marker.
*TIMP1 plus LCN2.
†CXCL16 plus TIMP1 plus LCN2.
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extremely rare worldwide. However, preoperative and postoperative
serum samples of three high-risk individuals from FPC families who
underwent prophylactic total pancreatectomy for intraductal papillary
mucinous neoplasm (IPMN)-like lesions onMRI and endoscopic ultra-
sonography were tested. All three patients had histologically confirmed
multifocal PanIN2/3 lesions but no invasive cancers. The LCN2 and
TIMP1 serum levels were above the calculated cutoff values (LCN2,
102 ng/ml; TIMP1, 273 ng/ml) in all three patients. The postoperative
serum levels of both markers, taken within 4 weeks after surgery,
dropped below the cutoff values in all three patients. This suggests that
the proposed biomarkers may indeed be suitable for early detection of
preneoplastic lesions of PC in high-risk individuals.
Discussion
As there is a definite need to improve upon the screening of individuals
at high risk of developing precursor lesions and ultimately PC, we tested
the ability of ELISAs to detect PC first in a transgenic mouse model
and then in human samples. The results of our study demonstrate that
the KPC mouse models of PC can be used to identify and test diag-
nostic markers. Comparative analysis of candidate biomarkers clearly
documented a similarity of serum levels in human and mice with dis-
tinct pancreatic lesions relative to normal specimens. The serum levels
of LCN2 and TIMP1 correlated with the severity of the neoplastic
changes in the pancreatic tissue in both mice and humans. The diag-
nostic model fitted for these two markers could reliably discriminate
between normal and precancerous/cancerous pancreatic lesions in our
training data set and thus might be a promising tool for PC screening
in high-risk individuals of FPC families. The two markers might be
most valuable for individuals from FPC families who present IPMN-
like lesions or unclear lesions on imaging. However, these data have to
be considered preliminary, especially due to the small number of FPC
patients with histologically verified PanIN2/3 lesions. The validation
of the diagnostic value of the serum marker combination LCN2 and
TIMP1 for the early detection of PC in a large cohort of high-risk
individuals of FPC families is now mandatory.
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